Articles Tagged With: RSV
-
Pandemic Fatigue, Disinformation Stunt Uptake of Respiratory Vaccines
A vaccination malaise that has beset much of the public appears to have extended to healthcare workers as well. In addition to citing an abysmal COVID-19 vaccination rate of 17% for healthcare workers during the 2022-2023 flu season, the Centers for Disease Control and Prevention pointed to a “lack of provider recommendation” as one of four key reasons patients are skipping immunizations, with the others being concerns about serious side effects, the occurrence of minor side effects, and a lack of time or forgetfulness.
-
Respiratory Syncytial Virus Infection During Pregnancy
Although women who developed respiratory syncytial virus (RSV) infection during pregnancy had a higher risk of preterm birth compared to those without RSV infection, the risk of miscarriage, stillbirth, low birth weight, and small for gestational age fetus were similar between the RSV and placebo groups.
-
Double Trouble: Vaccines Lag, Virulent Mpox Clade 1 Spreads
The Centers for Disease Control and Prevention has released two health advisory alerts only a week apart, one dealing with the “urgent need” to vaccinate people for seasonal respiratory viruses; the second warning that a virulent type of mpox (monkeypox) virus is spreading in Africa.
-
Respiratory Triple Play: Vaccination Is the Key
As a trifecta of viruses converge this fall and winter, the United States has an unprecedented infection control counterpunch: vaccines for the 2023-2024 flu season, new shots for respiratory syncytial virus, and the latest formula to protect against COVID-19.
-
CDC Recommends RSV Vaccine for Patients in Third Trimester
The agency says this solution should be administered to patients during weeks 32 through 36 of pregnancy to protect babies against the dangerous virus, both before and shortly after birth.
-
Nirsevimab-alip Injection (Beyfortus)
Nirsevimab can be prescribed to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season.
-
The Current State of RSV
Respiratory syncytial virus is a common virus encountered in the ED, with myriad presentations and complications that clinicians must be able to identify and manage. The authors provide state-of-the-art diagnostic and management strategies for the acute care clinician.
-
Respiratory Syncytial Virus Vaccine, Adjuvanted (Arexvy)
Arexvy can be administered to prevent lower respiratory tract disease caused by respiratory syncytial virus in patients age 60 years and older.
-
RSV Vaccine for Older Patients Receives Support
FDA approved Arexvy to protect people age 60 years and older against the respiratory syncytial virus.
-
FDA Panel Greenlights RSV Vaccine for Elderly
With some concerns and caveats that put a strong emphasis on post-marketing surveillance, vaccine advisors for the Food and Drug Administration have greenlit two vaccines against respiratory syncytial virus infections in people aged 60 years and older.